Dec 28, 2025 • Finviz
BULLISH
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (NASDAQ: JANX) is seen by Wall Street as having significant potential, with a consensus "buy" rating and high price targets suggesting substantial upside. Despite Barclays trimming its price target, the company recently provided a positive update on its Phase 1 study for JANX008, an EGFR-targeted TRACTr for various solid tumors. Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer.
Dec 27, 2025 • Insider Monkey
BULLISH
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (NASDAQ: JANX) is attracting significant Wall Street attention, with analysts issuing "buy" or equivalent ratings and high price targets. The company recently completed the Phase 1a dose-escalation portion of its JANX008 study for treating various solid tumors and is now initiating expansion cohorts. Despite acknowledging JANX's potential, the article suggests that some AI stocks may offer even greater returns and lower risk.
Dec 24, 2025 • Nasdaq
SOMEWHAT-BULLISH
Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence
Janux Therapeutics, Inc. has announced the completion of the Phase 1a dose-escalation portion of its Phase 1 study for JANX008, an EGFR-targeted Tumor Activated T Cell Engager. The company has now initiated expansion cohorts to further evaluate and optimize the dose across various solid tumor settings. JANX008, along with JANX007, represents one of Janux's two TRACTr therapeutic candidates currently in clinical trials.
Dec 24, 2025 • Business Wire
SOMEWHAT-BULLISH
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
Janux Therapeutics has provided an update on its ongoing Phase 1 study for JANX008, an EGFR-targeted T-Cell Engager (TRACTr) being developed for various solid tumor indications. The company has completed the Phase 1a dose-escalation portion and has initiated expansion cohorts to further evaluate and optimize dosing. Janux plans to release additional updates as the study progresses and more data becomes available.
Dec 23, 2025 • Investing.com Australia
SOMEWHAT-BULLISH
Janux completes phase 1a dose-escalation for EGFR cancer drug By Investing.com
Janux Therapeutics has completed the Phase 1a dose-escalation portion of its clinical trial for JANX008, an EGFR-targeted cancer immunotherapy, with expansion cohorts now initiated to further evaluate the drug in various solid tumor types. Despite a robust pipeline including other TRACTr candidates, analysts do not anticipate profitability this year, which is common for clinical-stage biotechnology companies. The company's financial flexibility is supported by holding more cash than debt on its balance sheet.
Dec 21, 2025 • Stock Traders Daily
SOMEWHAT-BEARISH
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing
This article analyzes Janux Therapeutics Inc. (JANX) using AI models to determine its impact on rotational strategy timing. Key findings indicate weak sentiment across all horizons, supporting a short bias, with an exceptional 173.0:1 risk-reward setup. The analysis provides specific entry, target, and stop-loss points for position trading, momentum breakout, and risk hedging strategies.